Table of Contents Table of Contents
Previous Page  855 860 Next Page
Information
Show Menu
Previous Page 855 860 Next Page
Page Background

incidence of device infection, but appears to have altered the

organisms most commonly causing infection

[3]

. Historically,

most wound infections for penile prostheses have been caused

by coagulase-negative

Staphylococcus

, which tends to cause a

local infection and is generally amenable to a salvage proce-

dure

[4]

. In the era of coated devices, we now witness organ-

isms that tend to present with earlier infections and systemic

symptoms and are less amenable to salvage. This manuscript

highlights the increasing prevalence of atypical organisms

that cause systemic symptoms and purulent infections.

Patients with systemic symptoms and purulent drainage are

not well served by a salvage operation, and should undergo

explantation of all device components. The question is what

antibiotics should be used perioperatively for prosthetic sur-

gery. We contend that patients with risk factors for infection

should have broader perioperative coverage than those

recommended by current guidelines. Vancomycin

[2_TD$DIFF]

and

[3_TD$DIFF]

ami-

noglycosides, both commonly used

[4_TD$DIFF]

for prosthetic cases in the

United States,

[5_TD$DIFF]

provide

[6_TD$DIFF]

coverage for MRSA and

[7_TD$DIFF]

gram

[8_TD$DIFF]

negative

[9_TD$DIFF]

organisms,

[10_TD$DIFF]

respectively. The real lesson from this article is the

need to consider adding antifungals (eg, fluconazole) both

locally and systemically in men with any increase in the risk

of penile prosthesis infection. Although the vast majority of

implantation surgeons use postoperative antibiotics, compar-

ative data are needed to evaluate the utility of this practice

[5]

.

Conflicts of interest:

The authors have nothing to disclose.

References

[1]

Pineda M, Burnett A. Penile prosthesis infections a review of risk factors, prevention, and treatment. Sex Med Rev 2016;4:389 98

.

[2]

Mulcahy JJ. Long-term experience with salvage of infected penile implants. J Urol 2000;163:481 2

.

[3]

Mandava SH, Serefoglu EC, Freier MT, et al. Infection retardant coated in fl atable penile prostheses decrease the incidence of infec- tion: a systematic review and meta-analysis. J Urol 2012;188: 1855 60

.

[4]

Carson CC. Diagnosis, treatment and prevention of penile prosthesis infection. Int J Impot Res 2003;15(Suppl 5):S139 46.

[5]

Katz DJ, Stember DS, Nelson CJ, Mulhall JP. Perioperative prevention of penile prosthesis infection: practice patterns among surgeons of SMSNA and ISSM. J Sex Med 2012;9:1705 12

.

Wayne J.G. Hellstrom

*

, Kenneth J. DeLay

Department of Urology, Tulane University School of Medicine, New Orleans,

LA, USA

*Corresponding author. Department of Urology, Tulane University School

of Medicine, 1430 Tulane Avenue 86-42, New Orleans, LA 70112, USA.

E-mail addresses:

whellst@tulane.edu

,

jdaigle6@tulane.edu

(W.

J. Hellstrom).

http://dx.doi.org/10.1016/j.eururo.2017.06.015

© 2017 European Association of Urology.

Published by Elsevier B.V. All rights reserved.

Re: Critical Analysis of Early Recurrence After Laparo-

scopic Radical Cystectomy in a Large Cohort by the ESUT

Albisinni S, Fossion L, Oderda M, et al

J Urol 2016;195:1710

7

Experts

summary:

This study characterizes unusual early disease recurrence

patterns among patients with favorable disease characteristics

undergoing laparoscopic radical cystectomy (RC). Of patients

with pT2 N0 R0 disease or less, 8.7% experienced recurrence

within 2 yr including many with disseminated disease or

bulky metastases. The authors conclude that technical factors

of minimally invasive surgery may have contributed to these

unexpected recurrences.

Experts

comments:

Although the explanation for the above findings is unclear,

they are thought provoking and cannot be ignored as a signal.

Similar questions were raised in a retrospective reviewof open

and robot-assisted RC, which observed a higher frequency of

extrapelvic nodal metastases and peritoneal carcinomatosis in

the latter group even though overall relapse rates were com-

parable

[1]

. These observations are not limited to urological

surgery and have been noted in gynecological and colorectal

malignancies.

Theoretical explanations proposed for observed higher

rates and distinct pattern of early recurrence include a

funnel

effect of the ports, lower intraperitoneal immune

response due to pneumoperitoneum, lower pH due to CO

2

insufflation that aids cell implantation, and pulsatile

pneumoperitoneum potentiating migration of vascular

tumor emboli. The use of the AirSeal device, which

maintains constant insufflation as opposed to the cyclic

insufflation typical of conventional systems, can theoreti-

cally obviate the former and latter effects but requires

further research.

Another concern is the Trendelenburg position

employed during minimally invasive RC (MIRC), which is

hypothesized to aid disease dissemination by potentiating

the flow of potentially malignant-cell containing irrigation

cranially. Reassuringly, a small study of pelvic irrigation

during robotic cystectomy did not find any malignant cells

on cytology

[2]

. However, it should be noted that the

majority of the cohort had favorable disease character-

istics, and therefore, this mechanism of tumor spread

cannot be confidently ruled out, especially in advanced

disease.

Strategies to prevent local recurrence after open RC have

included preoperative radiation and intravesical chemo-

therapy. Contemporary techniques include urethral cathe-

terization followed by clamping and clipping of ureters,

and/or suture ligation of urethra to prevent spillage

[3]

. Intraoperative instillation of mitomycin has been

employed during nephroureterectomy and could theoreti-

cally decrease relapse after RC

[4]

. Furthermore, intraperi-

toneal chemotherapy is administered during surgical

resection of other abdominopelvic malignancies to mini-

mize seeding and could be adopted in the MIRC setting.

Many of these safeguards have associated morbidity, and

thus patient selection is paramount. In those with carcino-

ma in situ (CIS), where a field change in the urothelium has

E U R O P E A N U R O L O GY 7 2 ( 2 0 17 ) 8 5 3

8 5 8

855